Charles River Laboratories International, Inc. (NYSE:CRL) CEO Purchases $1,002,435.75 in Stock

Charles River Laboratories International, Inc. (NYSE:CRL) CEO James C. Foster acquired 6,075 shares of the company’s stock in a transaction dated Thursday, February 20th. The shares were bought at an average cost of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now directly owns 183,639 shares in the company, valued at $30,302,271.39. The trade was a 3.42 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Charles River Laboratories International Price Performance

CRL stock opened at $163.11 on Monday. The firm’s 50-day moving average price is $172.84 and its two-hundred day moving average price is $188.00. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $275.00. The stock has a market capitalization of $8.34 billion, a price-to-earnings ratio of 1,087.39, a PEG ratio of 4.54 and a beta of 1.37. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. During the same quarter in the previous year, the company earned $2.46 earnings per share. The company’s revenue for the quarter was down 1.1% compared to the same quarter last year. As a group, equities analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Hedge Funds Weigh In On Charles River Laboratories International

A number of hedge funds have recently modified their holdings of CRL. Wellington Management Group LLP increased its position in shares of Charles River Laboratories International by 135,927.9% in the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock valued at $736,819,000 after acquiring an additional 3,738,018 shares during the period. D1 Capital Partners L.P. purchased a new position in shares of Charles River Laboratories International during the fourth quarter valued at about $172,752,000. Norges Bank purchased a new position in shares of Charles River Laboratories International during the fourth quarter valued at about $98,886,000. Nomura Holdings Inc. purchased a new position in shares of Charles River Laboratories International during the fourth quarter valued at about $56,820,000. Finally, Raymond James Financial Inc. purchased a new position in shares of Charles River Laboratories International during the fourth quarter valued at about $42,776,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on CRL shares. Morgan Stanley dropped their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a report on Wednesday, February 5th. Barclays dropped their price objective on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating for the company in a report on Tuesday, February 18th. William Blair downgraded shares of Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. StockNews.com downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Thursday, November 7th. Finally, Evercore ISI lifted their price objective on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. Three research analysts have rated the stock with a sell rating, thirteen have issued a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $195.71.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).